Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial D-918-2013

Avastin, (0.05 ml, 1.25 mg/0.05ml), single unit dose syringes, Clinical Specialties Compounding Pharmacy, Augusta, GA

Publicado el 4 de septiembre de 2013 · Inicio del retiro: 11 de marzo de 2013

Resumen

FDA registra el retiro D-918-2013 de medicamentos de Clase II, publicado el 4 de septiembre de 2013 e iniciado el 11 de marzo de 2013. Empresa responsable: Clinical Specialties Compounding Pharmacy; Estado: Finalizado; Cantidad reportada: 2190 syringes; Lote: Lot #CABDAHAC:39, Exp. Date: 5/8/2013; Lot #CABDAGAC:58, Exp. Date: 4/13/2013; Lot #CABDAHAC:77, Exp. Date: 4/8/2013; Lot #CABDBIAC:86, Exp. Date: 4/19/2013; Lot #CABDCFAC:29, Exp. Date: 4/26/2013; Lot #CABDAEAD:26, Exp. Date: 5/3/2013; Lot #CABDAEAC:47, Exp. Date: 5/5/2013; Lot #CABDAEAC:58, Exp. Date: 5/5/2013; Lot #CABDAFAC:46, Exp. Date: 5/6/2013; Lot #CABDAIAC:46, Exp. Date: 5/9/2013; Lot #CABDBCAC:94, Exp. Date: 5/13/2013; Lot #CABDCCAC:26, Exp. Date: 5/23/2013; Lot #CABDCFAC:81, Exp. Date: 5/26/2013; Lot #CABDABAD:05, Exp. Date: 5/30/2013; Lot #CABDAFAC:47, Exp. Date: 5/6/2013; Lot #CABDAGAC:43, Exp. Date: 5/7/2013; Lot #CABDBDAC:69, Exp. Date: 5/14/2013; Lot #CABDBIAC:77, Exp. Date: 5/19/2013; Lot #CABDCHAC:19, Exp. Date: 5/28/2013; Lot #CABDAHAD:21, Exp. Date: 6/5/2013; Lot #CABDCFAC:17, Exp. Date: 5/26/2013; Lot #CABDAHAD:00, Exp. Date: 6/5/2013; Lot #CABDBCAC:47, Exp. Date: 5/13/2013; Lot #CABDCBAC:97, Exp. Date: 5/22/2013; Lot #CABDAGAC:08, Exp. Date: 5/7/2013; Lot #CABDBCAC:15, Exp. Date : 5/13/2013; Lot #CABDBDAC:17, Exp. Date: 5/14/2013; Lot #CABDCIAC:42, Exp. Date : 5/29/2013; Lot #CABDBEAC:44, Exp. Date: 5/15/2013; Lot #CABDCBAC:79, Exp. Date: 5/22/2013; Lot #CABDCIAC:00, Exp. Date : 5/29/2013; Lot #CABDAHAD:82, Exp. Date : 6/5/2013; Lot #CABDCBAC:31, Exp. Date: 5/22/2013; Lot #CABDCIAB:68, Exp. Date: 4/28/2013; Lot #CABDCJAB:59, Exp. Date: 4/29/2013; Lot #CABDDBAB:93, Exp. Date: 5/1/2013; Lot #CABCCGBC:92, Exp. Date: 2/24/2013; Lot #CABCCGBC:49, Exp. Date: 3/26/2013; Lot #CABCCIBC:39, Exp. Date: 3/23/2013; Lot #CABCDBBC:71, Exp. Date: 3/1/2013; Lot #CABDACAB:56, Exp. Date: 4/2/2013; Lot #CABDACAB:76, Exp. Date: 4/2/2013; Lot #CABDACAB:89, Exp. Date: 4/2/2013; Lot #CABDADAB:69, Exp. Date: 4/3/2013; Lot #CABDADAB:93, Exp. Date: 4/3/2013; Lot #CABDADAB:54, Exp. Date: 4/3/2013; Lot #CABDAEAB:96, Exp. Date: 4/4/2013; Lot #CABDAHAB:00, Exp. Date: 4/7/2013; Lot #CABDAHAB:59, Exp. Date: 4/7/2013; Lot #CABDAHAB:18, Exp. Date: 4/7/2013; Lot #CABDAJAB:30, Exp. Date: 4/9/2013; Lot #CABDAJAB:70, Exp. Date: 4/9/2013; Lot #CABDAJAB:97, Exp. Date: 4/9/2013; Lot #CABDBAAB:63, Exp. Date: 4/10/2013; Lot #CABDBAAB:77, Exp. Date: 4/10/2013; Lot #CABDBAAB:54, Exp. Date: 4/10/2013; Lot #CABDBAAB:04, Exp. Date: 4/10/2013; Lot #CABDBEAB:97, Exp. Date: 4/14/2013; Lot #CABDBFAB:67, Exp. Date: 3/16/2013; Lot #CABDBFAB:61, Exp. Date: 4/15/2013; Lot #CABDBFAB:84, Exp. Date: 4/15/2013; Lot #CABDBGAB:34, Exp. Date: 4/16/2013; Lot #CABDBHAB:33, Exp. Date: 4/17/2013; Lot #CABDBHAB:71, Exp. Date: 4/17/2013; Lot #CABDBHAB:75, Exp. Date: 4/17/2013; Lot #CABDCBAB:66, Exp. Date: 4/21/2013; Lot #CABDCCAB:64, Exp. Date: 4/22/2013; Lot #CABDCDAB:38, Exp. Date: 4/23/2013; Lot #CABDCEAB:71, Exp. Date: 4/24/2013; Lot #CABDCEAB:04, Exp. Date: 4/24/2013; Lot #CABDCFAB:22, Exp. Date: 3/26/2013; Lot #CABDCFAB:14, Exp. Date: 4/25/2013; Lot #CABDCIAB:51, Exp. Date: 4/28/2013; Lot #CABDCIAB:93, Exp. Date: 3/29/2013; Lot #CABDDBAB:71, Exp. Date: 4/1/2013; Lot #CABCBJBC:00, Exp. Date: 3/19/2013; Lot #CABCCGBC:30, Exp. Date: 3/26/2013; Lot #CABCCHBC:55, Exp. Date: 3/27/2013 and Lot #CABCDBBC:87, Exp. Date: 3/31/2013. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Lack of Assurance of Sterility; product linked to adverse event reports of endophthalimitis eye infections and FDA inspection findings resulted in concerns regarding quality control processes

Qué hacer

Voluntary: Firm initiated · Telephone

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Clinical Specialties Compounding Pharmacy
Distribuidor
FL, GA, IN, LA and SC.
Lote
Lot #CABDAHAC:39, Exp. Date: 5/8/2013; Lot #CABDAGAC:58, Exp. Date: 4/13/2013; Lot #CABDAHAC:77, Exp. Date: 4/8/2013; Lot #CABDBIAC:86, Exp. Date: 4/19/2013; Lot #CABDCFAC:29, Exp. Date: 4/26/2013; Lot #CABDAEAD:26, Exp. Date: 5/3/2013; Lot #CABDAEAC:47, Exp. Date: 5/5/2013; Lot #CABDAEAC:58, Exp. Date: 5/5/2013; Lot #CABDAFAC:46, Exp. Date: 5/6/2013; Lot #CABDAIAC:46, Exp. Date: 5/9/2013; Lot #CABDBCAC:94, Exp. Date: 5/13/2013; Lot #CABDCCAC:26, Exp. Date: 5/23/2013; Lot #CABDCFAC:81, Exp. Date: 5/26/2013; Lot #CABDABAD:05, Exp. Date: 5/30/2013; Lot #CABDAFAC:47, Exp. Date: 5/6/2013; Lot #CABDAGAC:43, Exp. Date: 5/7/2013; Lot #CABDBDAC:69, Exp. Date: 5/14/2013; Lot #CABDBIAC:77, Exp. Date: 5/19/2013; Lot #CABDCHAC:19, Exp. Date: 5/28/2013; Lot #CABDAHAD:21, Exp. Date: 6/5/2013; Lot #CABDCFAC:17, Exp. Date: 5/26/2013; Lot #CABDAHAD:00, Exp. Date: 6/5/2013; Lot #CABDBCAC:47, Exp. Date: 5/13/2013; Lot #CABDCBAC:97, Exp. Date: 5/22/2013; Lot #CABDAGAC:08, Exp. Date: 5/7/2013; Lot #CABDBCAC:15, Exp. Date : 5/13/2013; Lot #CABDBDAC:17, Exp. Date: 5/14/2013; Lot #CABDCIAC:42, Exp. Date : 5/29/2013; Lot #CABDBEAC:44, Exp. Date: 5/15/2013; Lot #CABDCBAC:79, Exp. Date: 5/22/2013; Lot #CABDCIAC:00, Exp. Date : 5/29/2013; Lot #CABDAHAD:82, Exp. Date : 6/5/2013; Lot #CABDCBAC:31, Exp. Date: 5/22/2013; Lot #CABDCIAB:68, Exp. Date: 4/28/2013; Lot #CABDCJAB:59, Exp. Date: 4/29/2013; Lot #CABDDBAB:93, Exp. Date: 5/1/2013; Lot #CABCCGBC:92, Exp. Date: 2/24/2013; Lot #CABCCGBC:49, Exp. Date: 3/26/2013; Lot #CABCCIBC:39, Exp. Date: 3/23/2013; Lot #CABCDBBC:71, Exp. Date: 3/1/2013; Lot #CABDACAB:56, Exp. Date: 4/2/2013; Lot #CABDACAB:76, Exp. Date: 4/2/2013; Lot #CABDACAB:89, Exp. Date: 4/2/2013; Lot #CABDADAB:69, Exp. Date: 4/3/2013; Lot #CABDADAB:93, Exp. Date: 4/3/2013; Lot #CABDADAB:54, Exp. Date: 4/3/2013; Lot #CABDAEAB:96, Exp. Date: 4/4/2013; Lot #CABDAHAB:00, Exp. Date: 4/7/2013; Lot #CABDAHAB:59, Exp. Date: 4/7/2013; Lot #CABDAHAB:18, Exp. Date: 4/7/2013; Lot #CABDAJAB:30, Exp. Date: 4/9/2013; Lot #CABDAJAB:70, Exp. Date: 4/9/2013; Lot #CABDAJAB:97, Exp. Date: 4/9/2013; Lot #CABDBAAB:63, Exp. Date: 4/10/2013; Lot #CABDBAAB:77, Exp. Date: 4/10/2013; Lot #CABDBAAB:54, Exp. Date: 4/10/2013; Lot #CABDBAAB:04, Exp. Date: 4/10/2013; Lot #CABDBEAB:97, Exp. Date: 4/14/2013; Lot #CABDBFAB:67, Exp. Date: 3/16/2013; Lot #CABDBFAB:61, Exp. Date: 4/15/2013; Lot #CABDBFAB:84, Exp. Date: 4/15/2013; Lot #CABDBGAB:34, Exp. Date: 4/16/2013; Lot #CABDBHAB:33, Exp. Date: 4/17/2013; Lot #CABDBHAB:71, Exp. Date: 4/17/2013; Lot #CABDBHAB:75, Exp. Date: 4/17/2013; Lot #CABDCBAB:66, Exp. Date: 4/21/2013; Lot #CABDCCAB:64, Exp. Date: 4/22/2013; Lot #CABDCDAB:38, Exp. Date: 4/23/2013; Lot #CABDCEAB:71, Exp. Date: 4/24/2013; Lot #CABDCEAB:04, Exp. Date: 4/24/2013; Lot #CABDCFAB:22, Exp. Date: 3/26/2013; Lot #CABDCFAB:14, Exp. Date: 4/25/2013; Lot #CABDCIAB:51, Exp. Date: 4/28/2013; Lot #CABDCIAB:93, Exp. Date: 3/29/2013; Lot #CABDDBAB:71, Exp. Date: 4/1/2013; Lot #CABCBJBC:00, Exp. Date: 3/19/2013; Lot #CABCCGBC:30, Exp. Date: 3/26/2013; Lot #CABCCHBC:55, Exp. Date: 3/27/2013 and Lot #CABCDBBC:87, Exp. Date: 3/31/2013
Clasificación de riesgo
Class II
Área (FDA)
drug
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿Avastin, (0.05 ml, 1.25 mg/0.05ml), single unit dose syringes, Clinical Specialties Compounding Pharmacy, Augusta, GA fue retirado del mercado?

Sí. FDA publicó el retiro D-918-2013 el 4 de septiembre de 2013. Peligro reportado: Lack of Assurance of Sterility; product linked to adverse event reports of endophthalimitis eye infections and FDA inspection findings resulted in concerns regarding quality control processes

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Telephone